Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azacitidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 known ✓ | P26358 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | HBB | P68871 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.64 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.64 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azacitidine SCHEMBL169369 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL17537438 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL20143987 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL10024703 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL13390797 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL23815524 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL19996985 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Fazarabine SCHEMBL3278 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL1249475 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 | |
| Azacitidine SCHEMBL7146234 | 1.00 | LMNA (1.00) | LMNAMTORDNMT1TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200163995-A1 | PHARMACEUTICAL KIT AND USES THEREOF | JOHNPRO BIOTECH INC. (TW) | 2020-05-28 | — | — | US | claimed |
| WO-2019029351-A1 | PHARMACEUTICAL KIT AND USES THEREOF | JOHNPRO BIOTECH INC. (CN) | 2019-02-14 | — | — | WO | claimed |
| US-8470522-B2 | Three-dimensional culture containing human articular chondrocytes with induced terminal differentiation changes and preparation process and uses of the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2013-06-25 | — | — | US | claimed |
| WO-2013059357-A1 | METHODS, KITS, AND COMPOSITIONS FOR STEM CELL SELF-RENEWAL | STOWERS INSTITUTE FOR MEDICAL RESEARCH (US) | 2013-04-25 | — | — | WO | claimed |
| US-20130046171-A1 | DEVICE AND METHOD FOR ACCESSING AND TREATING DUCTS OF MAMMARY GLANDS | ATOSSA THERAPEUTICS, INC. | 2013-02-21 | — | — | US | claimed |
| US-20100069781-A1 | DEVICE AND METHOD FOR ACCESSING AND TREATING DUCTS OF MAMMARY GLANDS | ATOSSA THERAPEUTICS, INC. | 2010-03-18 | — | — | US | claimed |
| WO-2009129352-A2 | DEVICE AND METHOD FOR ACCESSING AND TREATING DUCTS OF MAMMARY GLANDS | WINDY HILL MEDICAL (US) | 2009-10-22 | — | — | WO | claimed |
| US-20080026362-A1 | Three-dimensional culture containing human articular chondrocytes with induced terminal differentiation changes, and preparation process and uses of the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2008-01-31 | — | — | US | claimed |
| WO-2007016037-A2 | METHODS FOR TRANS-DIFFERENTIATING CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-02-08 | — | — | WO | claimed |
| US-6932777-B2 | Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2005-08-23 | — | — | US | claimed |
| US-6656918-B2 | Contacting the ductal epithelium of the exocrine gland with epithelium destroying agents such as ethanol and vaccinia virus | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE | 2003-12-02 | — | — | US | claimed |
| US-12071450-B2 | Salts of conjugates for cancer therapy | BIOSIGHT LTD. (IL) | 2024-08-27 | — | — | US | disclosed |
| US-11845991-B2 | Fecal sample processing and analysis comprising detection of blood | EXACT SCIENCES CORPORATION (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230313317-A1 | FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD | JPMORGAN CHASE BANK, N.A. | 2023-10-05 | — | — | US | disclosed |
| US-20210395285-A1 | SALTS OF CONJUGATES FOR CANCER THERAPY | BIOSIGHT LTD. (IL) | 2021-12-23 | — | — | US | disclosed |
| US-20010005505-A1 | DESTRUCTION OF THE EPITHELIUM OF AN EXOCRINE GLAND IN THE PROPHYLACTIC AND THERAPEUTIC TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-06-28 | — | — | US | disclosed |
| WO-2000073326-A2 | REDOX-STABLE, NON-PHOSPHORYLATED CYCLIC PEPTIDE INHIBITORS OF SH2 DOMAIN BINDING TO TARGET PROTEIN, CONJUGATES THEREOF, COMPOSITIONS AND METHODS OF SYNTHESIS AND USE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-12-07 | — | — | WO | disclosed |
| US-6153184-A | CONTACTING, BY DUCTAL CANNULATION, THE DUCTAL EPITHELIUM OF THE EXOCRINE GLAND WITH A CYTOLYTIC VIRUS TO DESTROY LESS THAN ALL OF THE DUCTAL EPITHELIUM SO AS TO INHIBIT FORMATION OF CANCER OF DUCTAL EPITHELIAL ORIGIN | JOHN HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2000-11-28 | — | — | US | disclosed |
| US-5763415-A | Destruction of the epithelium of an exocrine gland in the prophylactic and therapeutic treatment of cancer | JOHN HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 1998-06-09 | — | — | US | disclosed |
| WO-1997005898-A1 | DELIVERY OF AN AGENT TO THE DUCTAL EPITHELIUM IN THE PROPHYLACTIC AND THERAPEUTIC TREATMENT OF CANCER | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 1997-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12071450-B2 | Salts of conjugates for cancer therapy | SLC7A11, SLC7A1, SLC1A5 | DNMT1 898/4885LMNA 3241/4885MTOR 3459/4885 |
| US-20210395285-A1 | SALTS OF CONJUGATES FOR CANCER THERAPY | SLC7A11, SLC7A1, SLC1A5 | DNMT1 898/4885LMNA 3241/4885MTOR 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.